What is ICD-10 code C69.20?

C69.20 is the ICD-10-CM diagnosis code for Malignant neoplasm of unspecified retina. A cancerous tumor of the retina (the light-sensitive tissue at the back of the eye) when the specific side is not documented. It belongs to the ICD-10-CM chapter for neoplasms (c00-d49). C69.20 is a billable code, meaning it can be reported on a claim as a primary or secondary diagnosis when supported by documentation. C69.20 is part of the FY2026 ICD-10-CM code set published by the CMS National Center for Health Statistics and used on Medicare, Medicaid, and commercial claims in the United States.

Yes. C69.20 is a billable ICD-10-CM code that can be reported on professional and institutional claims as a primary or secondary diagnosis when the provider documentation supports the specific condition described. Billable codes in ICD-10-CM are coded to the highest level of specificity available for the documented diagnosis. C69.20 is current for fiscal year 2026 and remains in the active CMS ICD-10-CM code set published by the National Center for Health Statistics.

What is the V28 vs V24 difference for C69.20?

CMS phased in the V28 risk adjustment model over payment years 2024 (33%), 2025 (67%), and 2026 (100%), replacing V24. V28 consolidates HCC categories, removes some lower-acuity conditions, and recalibrates RAF weights across the entire model. For C69.20, V28 maps to Prostate, Breast, and Other Cancers and Tumors at RAF 0.186 while V24 mapped to Breast, Prostate, and Other Cancers and Tumors at RAF 0.150. Both models can still appear in legacy data and in payer-specific lookback periods.

What should coders know when reporting C69.20?

Use this code only when laterality cannot be determined from documentation; query provider if side is documented elsewhere Retinal malignancies are often melanomas; ensure pathology confirms diagnosis before coding Because C69.20 maps to a payment HCC, the documentation must also satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's risk adjustment score.

2026 ICD-10-CM C69.20: Malignant neoplasm

ICD-10-CM Code View

HCC Buddy Code Card

Digital ICD-10 code-book layout with official code detail, always-visible risk models, Code Trumping, and Buddy coding guidance.

Code lookupC69.20Effective periodFY2026 Apr Update (Apr 1-Sep 30)

FY 2026 Apr update / Neoplasms (C00-D49) / Malignant neoplasms of eye, brain and other parts of central nervous system (C69-C72)

C69.20

Billable / SpecificICD-10-CMOfficial ICD-10-CMCodebook guidance

Malignant neoplasm of unspecified retina

A cancerous tumor of the retina (the light-sensitive tissue at the back of the eye) when the specific side is not documented.

Buddy Insight

Retinal malignancy encompasses two primary entities: retinoblastoma in children and uveal/retinal melanoma in adults.

CMS-HCC V28

Mapped

HCC 23

Prostate, Breast, and Other C...

RAF 0.186

CMS-HCC V24

Mapped

HCC 12

Breast, Prostate, and Other C...

RAF 0.150

ACA/HHS

Mapped

HCC 12

HHS-HCC 12

Varies by metal level

ESRD/PACE

Mapped

HCC 12

Breast, Prostate, and Other C...

RAF 0.045

RXHCC

Mapped

HCC 22

Cancer, Other Specified Sites

RAF 0.124

Code Book Path

Official

C69Malignant neoplasm of eye and adnexa

C69.2Malignant neoplasm of retina

C69.20Malignant neoplasm of unspecified retina

Inclusion Terms

Official

ICD-10-CM does not list inclusion terms for C69.20 in this effective period.

Excludes 2

Official

ICD-10-CM does not list Excludes 2 notes for C69.20 in this effective period.

Related Child Codes

Official

C69.21Malignant neoplasm of right retina

C69.22Malignant neoplasm of left retina

Includes

Official

ICD-10-CM does not list Includes notes for C69.20 in this effective period.

Excludes 1

Official

dark area on retina (D49.81)
neoplasm of unspecified behavior of retina and choroid (D49.81)
retinal freckle (D49.81)

Code First

Official

ICD-10-CM does not list Code First sequencing instructions for C69.20 in this effective period.

Use Additional

Official

ICD-10-CM does not list Use Additional Code instructions for C69.20 in this effective period.

Code Also

Official

ICD-10-CM does not list Code Also instructions for C69.20 in this effective period.

Buddy Documentation Tip

HCC Buddy guidance

Pathology or clinical diagnosis confirming malignancy (retinoblastoma versus melanoma versus other)

Laterality — this unspecified code requires a query when the affected eye can be identified

Tumor size, location on the retina, and extent of involvement

Staging (International Intraocular Retinoblastoma Classification for retinoblastoma, or AJCC for melanoma)

MEAT Support

HCC Buddy guidance

Pathology or clinical diagnosis confirming malignancy (retinoblastoma versus melanoma versus other)

Laterality — this unspecified code requires a query when the affected eye can be identified

Tumor size, location on the retina, and extent of involvement

Staging (International Intraocular Retinoblastoma Classification for retinoblastoma, or AJCC for melanoma)

Audit Caution

HCC Buddy guidance

Using unspecified laterality when the affected eye is documented in ophthalmology records

Confusing retinal with choroidal melanoma — different primary sites with different prognoses

Coding metastatic cancer to the retina as primary retinal cancer

Common Mistakes

HCC Buddy guidance

C69.21/C69.22 — Right/left retina: always use laterality-specific codes when the affected eye is known

C69.30-C69.32 — Choroidal malignancy: the choroid is beneath the retina; verify which layer is the primary site

C79.49 — Secondary malignant neoplasm of other parts of nervous system: metastatic cancer to the retina uses secondary codes

D31.20-D31.22 — Benign neoplasm of retina: confirm malignancy before using C69 codes

Current with CMS: FY2026 ICD-10-CM Apr 1 update (effective Apr 1 – Sep 30, 2026) · CMS-HCC V28, 100% phased in for payment year 2026. FY2027 code set already staged for October 1, 2026. How HCC Buddy stays current →

Is C69.20 an HCC code?

Yes. C69.20 (Malignant neoplasm of unspecified retina) maps to Prostate, Breast, and Other Cancers and Tumors under the CMS-HCC V28 risk adjustment model (and Breast, Prostate, and Other Cancers and Tumors under V24), with a community non-dual aged RAF of 0.186. It is billable for payment year 2026.

Coder answer: C69.20 is billable and maps to V28 HCC 23, Prostate, Breast, and Other Cancers and Tumors. Open it in the Code Book for the tabular path, RAF, and MEAT checklist.

Code: C69.20
Description: Malignant neoplasm of unspecified retina
HCC (V28): HCC 23 — Prostate, Breast, and Other Cancers and Tumors
RAF: 0.186
Billable: Yes
Payment year: 2026

HCC Category Mapping

V28HCC 23, Prostate, Breast, and Other Cancers and Tumors

0.186

V24HCC 12, Breast, Prostate, and Other Cancers and Tumors

0.150

ESRDHCC 12, Breast, Prostate, and Other Cancers and Tumors

0.045

RxHCCHCC 22, Cancer, Other Specified Sites

0.124

Each model's RAF is its CMS base weight for that model's standard population, so weights are not directly comparable across models: CMS-HCC V28 and V24 use Community, Non-Dual, Aged; ESRD uses the dialysis continuing-enrollee model; RxHCC is the Part D continuing-enrollee, non-low-income, aged weight (a larger scale than CMS-HCC). ACA/HHS has no single weight — it varies by metal level. Actual per-patient RAF contribution depends on member segment, interactions, and the model year used by the payer. V28 is the CMS-HCC model phased in over payment years 2024–2026; V24 remains in use during the transition and for historical data.

Work C69.20 in the Code Book — tabular path, V28 RAF, and MEAT checklist →

MEAT Criteria for C69.20

For C69.20 to count as a valid HCC diagnosis in a given encounter, the provider's documentation must show MEAT: Monitor, Evaluate, Assess, or Treat. A diagnosis from a prior year does not carry forward automatically, it has to be re-documented and supported each calendar year.

MMonitor: signs, symptoms, disease progression, or lab trending documented in the note
EEvaluate: test results, medication response, or physical findings reviewed by the provider
AAssess: explicit mention in the assessment or plan with acknowledgment of status
TTreat: medication, referral, procedure, therapy, or counseling tied to the diagnosis

Only one of M/E/A/T is required to support the code, but the documentation must be specific enough to show that the provider actually addressed C69.20 during that encounter, not just copy-forwarded from a problem list.

Coder workflow notes

Get the V28 RAF + MEAT cheat sheet

One printable page: confirm a code's V28 HCC status, its RAF weight, and the MEAT your note needs to make it stick. Free, no card.

Free PDF. No card. Unsubscribe anytime.

What This Code Means

C69.20 is the ICD-10-CM diagnosis code for malignant neoplasm of unspecified retina. A cancerous tumor of the retina (the light-sensitive tissue at the back of the eye) when the specific side is not documented. C69.20 sits in the ICD-10-CM chapter for neoplasms (c00-d49), within the section covering malignant neoplasms of eye, brain and other parts of central nervous system (c69-c72).

Under the CMS-HCC V28 risk adjustment model, C69.20 maps to Prostate, Breast, and Other Cancers and Tumors (HCC 23) with a community, non-dual, aged base RAF weight of 0.186. Under the older CMS-HCC V24 model, C69.20 maps to Breast, Prostate, and Other Cancers and Tumors (HCC 12) with a community, non-dual, aged base RAF weight of 0.150. V28 is the CMS-HCC risk adjustment model that reached 100% phase-in for payment year 2026, replacing V24 which was used during the PY2024–PY2025 transition.

Use this code only when laterality cannot be determined from documentation; query provider if side is documented elsewhere. Because C69.20 maps to a payment HCC, the provider's documentation must satisfy MEAT criteria (Monitor, Evaluate, Assess, or Treat) for the encounter to count toward the patient's Medicare Advantage risk adjustment score. When documentation is ambiguous, coders should issue a provider query rather than assume the highest-specificity variant.

HCC Buddy maintains structured V28 and V24 mapping, RAF weights, and MEAT documentation criteria for C69.20 sourced directly from the CMS-HCC risk adjustment model files and the CMS ICD-10-CM code set.

Coding Tips

•Use this code only when laterality cannot be determined from documentation; query provider if side is documented elsewhere
•Retinal malignancies are often melanomas; ensure pathology confirms diagnosis before coding

Clinical Significance

Retinal malignancy encompasses two primary entities: retinoblastoma in children and uveal/retinal melanoma in adults. Both are serious sight-threatening and potentially life-threatening conditions. Retinal cancers require specialized treatment including enucleation, radiation, or chemotherapy, making them high-resource diagnoses for risk adjustment.

Documentation Requirements

✓Pathology or clinical diagnosis confirming malignancy (retinoblastoma versus melanoma versus other)
✓Laterality — this unspecified code requires a query when the affected eye can be identified
✓Tumor size, location on the retina, and extent of involvement
✓Staging (International Intraocular Retinoblastoma Classification for retinoblastoma, or AJCC for melanoma)
✓Genetic testing results if applicable (RB1 gene for retinoblastoma)

Commonly Confused Codes

•C69.21/C69.22: Right/left retina: always use laterality-specific codes when the affected eye is known
•C69.30-C69.32: Choroidal malignancy: the choroid is beneath the retina; verify which layer is the primary site
•C79.49: Secondary malignant neoplasm of other parts of nervous system: metastatic cancer to the retina uses secondary codes
•D31.20-D31.22: Benign neoplasm of retina: confirm malignancy before using C69 codes